Skip to content


  • Poster presentation
  • Open Access

Dendritic cell-derived exosomes (Dex) are potential biomarkers of response to Ipilimumab in metastatic melanoma

  • 1,
  • 1,
  • 2,
  • 1,
  • 2,
  • 2,
  • 2,
  • 2 and
  • 1
Journal of Translational Medicine201513 (Suppl 1) :P15

  • Published:


  • Melanoma
  • Overall Survival
  • CD86 Expression
  • Metastatic Melanoma
  • Melanoma Patient


Chemotherapy and vaccination with tumor-loaded dendritic cells (DCs) show poor impact on overall survival (OS) in metastatic melanoma1,2. Ipilimumab (IPI) improves OS throughout the blockade of CTLA4-mediated inhibitory signals in T-cells and restores the efficiency of the antigenic cross-priming by mature (m) DCs3. However, variation of immune cells to evaluate the response to IPI does not reflect the T-cell activation and is a modest predictor of clinical response. Recent studies in human and experimental melanoma demonstrated that mDCs release endomysial microvescicles namely dexosomes (Dex) showing a functional anti-melanoma activity as well as an antigenic profile resembling that of circulating mDCs including CD40, CD80 and CD86 co-stimulatory molecules.

This research is aimed to identify an early biomarker of T-cell activation for predicting the clinical response in IPI-treated melanoma patients.


Thirthy-four patients with metastatic melanoma were treated with IPI and sera collected at each infusion. Serum Dex were purified by the ‘Total Exosome Isolation kit’ (Invitrogen) and conjugated with magnetic beads of 4 μm of diameter (Dynabeads). Dex were first identified by size and then CD40, CD80 and CD86 expression was evaluated by flow-cytometry using relative MoAbs. The response to IPI was analyzed up to 12 weeks after the end of treatment, according to RECIST criteria. Moreover, DEX levels were compared with clinical and immunological parameters by the Mann-Withnet test.


Both CD40 and CD80 expression was unchanged after the end of IPI treatment with respect to basal levels, whereas a significant increase of Dex-CD86 expression occurred as compared to baseline (21.3±1.5% vs 12.0±0.8%, p<0.05) in 5 patients with partial response and 1 in complete remission (19.4±1.2% vs. 9.9±1.1%). A weak trend to the increment of Dex-CD86 occurred in patients with stable disease, while those in clinical progression showed low levels in all instances. CD86 expression was apparently unrelated to LDH levels and absolute leukocyte count.


Level of CD86 expressed by Dex reflects the immunological activation in melanoma patients treated with IPI. Therefore, the measurement of soluble Dex-CD86 could be an early marker of response to IPI and predict the efficiency of immunological response.

Authors’ Affiliations

Medical Oncology Unit - Department of Biomedical Sciences and Clinical Oncology, University of Bari, Italy
Melanoma, Cancer Immunotherapy and Innovative Therpay Unit - INT “G.Pascale”, Napoli, Italy


© Stefania et al; licensee BioMed Central Ltd. 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.